Vildagliptin

Chenglian Pharmaceutical is an innovative high-tech pharmaceutλical enterprise that is market-oriented and realizes industrial development thr↔ough R&D innovation and technology transformation.

key word:

Pharmaceutical technology

Category:

Product Description

Integrity, innovation, cooperation, sharing, win-win

The company integrates multiple resources and strives to build a large hea£lth industry finance platform company integrating pharmaceutical, intelligent medica✔l, bio pharmaceutical R&D, industrial production and sales.

The chemical reactions involved in the existing products in♦clude Foucault reaction, nitration reaction, sulfonationλ reaction, hydrogenation reaction, fluorination reaction, chlorinatioφn reaction, bromination reaction, diazotization reaction≤, format reaction, etc.

Related products

Sitagliptin Phosphate Monohydrate

Sitagliptin phosphate is a dipeptidyl peptidase-4 (DPP4) inhibitor developed by Merck. In Octobe r 2006, Sitagliptin phosphate Januvia was approved by FDA as the first DPP4 ∑inhibitor for the treatment of type ⅱ diabetes mellitus. The characteristics  of this drug are that it can stimulate insulin secretion while reducing hunger without caus♦ing weight gain. Hypoglycemia and edema will not occur, an∑d it is suitable for diabetic patients with poor blood glucose control and frequent> hypoglycemia.

Sumatriptan Succinate

Medication for migraine

Vildagliptin

Chenglian Pharmaceutical is an innovative high-tech pharmaceutical enterprise that is market-o∑riented and realizes industrial development through R&D i✔nnovation and technology transformation.

Ketoprofen

The non-steroidal anti-inflammatory drug ketoprofen is one of the most important products for t↕he treatment of arthritis. It is well tolerated and has a low incidence of side effects

Pranlukast

Pranlukast, developed by Ono, is one of the three  major leukotriene receptor antagonists. In clinical application, it has good therapeutic ef fect on atopic asthma and other types of bronchial asthma, and the market prospe€ct is huge. In the major category of asthma drugs, leukotriene receptor antagonists have th‌e fastest growing market share.

Avanafil

Chenglian Pharmaceutical is an innovative high-tech pharmaceuti±cal enterprise that is market-oriented and realizes indu‌strial development through R&D innovation and technology transformation.

Donepezil HCL

Treatment of mild to moderate Alzheimer's syndrome. It is the second drug approved byδ FDA for Alzheimer's disease in the United States. Its treatment reaches the♠ target dose and has low toxic and side effects. Itγ has been widely recognized by our medical community, and good to¥lerance is its biggest advantage. In October 1999, Donepezil w♣as launched in China under the trade name "Aricept", which is the main chemical drug against AlzheiΩmer's disease. At present, CFDA has approved a numb‌er of domestic enterprises to produce donepezil preparations, theΩ main dosage forms are tablets, capsules, dispersive tablets, oral disintegrating tablets±.

Almotriptan

Migraine medication for adolescents

Apixaban

English name Apixaban Trade name ELIQUIS, tablet: Apixaban (Eliquis, Bristol-Myers Squibb/Pfizer),¥ a direct oral factor Xa inhibitor, was approved for use in πthe 27 EU member states. The world's first drug app♣roved to prevent venous thromboembolism (VTE) in adult patien×ts undergoing elective hip or knee replacement. From June 2019 to June Ω2020, the annual sales of apixaban products overseas reached about Ω$15.4 billion, with a year-on-year growth of nearly 32%, and the API consumption reached about ¶23,960 kg, with a year-on-year growth of about 28%. Compaφred with its main competitor, Rivaroxaban, the drug's ‍annual overseas sales are about $4.5 billion higher.

Lenvatinib

Chenglian Pharmaceutical is an innovative high-tech pharmaceutical enterprise that is market-orient↓ed and realizes industrial development through R&D innovation and t♥echnology transformation.

Clofarabine

It is a nucleotide analogue developed by Bioenvision and manufactured by Genzyme. On Decemb₩er 29, 2004, it was approved by FDA for the treatment of refractory or relapsed aαcute lymphoblastic leukemia (ALL) in children.

Upadacitinib(Scientific research)

Chenglian Pharmaceutical is an innovative high-tech pharmaceutical enterpriseλ that is market-oriented and realizes industrial development through R&D innovation and t•echnology transformation.

Product Consulting

Our staff will contact you within 24 hours (working days). If you need other service£s, E-mail: 2880705932@qq.com
Submit